Golub Capital delivered another year of "good boring," consistent results for its stakeholders in 2025, aided by its ...
First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved ...
Round led by new investor Life Sciences at Goldman Sachs Alternatives with participation by new investor the Retinal Degeneration Fund, and supported by existing investorsFunds will advance laru-zova ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback